Form 4: Surrozen Director Shao-Lee Lin Reports Option Grant

Director Shao-Lee Lin reports the acquisition of options to purchase 1,333 shares of Surrozen, Inc. common stock.

Summary

• On June 5, 2024, Shao-Lee Lin, a director of Surrozen, Inc., was granted options to purchase 1,333 shares of the company's common stock.
• The exercise price of the options is $11.
• The options vest annually from the grant date, contingent upon continuous service as a director, and expire on June 5, 2034.
• The transaction was reported on a Form 4 filed with the SEC on June 6, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding an option grant, and does not contain information that would significantly impact sentiment positively or negatively.

Positives

• The grant of options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Option grants to directors are a common practice in publicly traded companies to incentivize and align their interests with those of shareholders. This is a standard form 4 filing related to such a grant.

Comparison to Industry Standards

• Option grants to directors are a standard practice across the biotechnology industry.
• The size of the grant (1,333 shares) would need to be compared to grants made to directors at comparable companies (e.g., other small-cap biotech firms) to assess its relative significance.
• Companies like BioNTech, Moderna, and Regeneron Pharmaceuticals also use stock options as part of their compensation packages for directors and executives.

Stakeholder Impact

• The option grant aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates